{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:31:09Z","timestamp":1787653869097,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10067-025-07641-3","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T20:48:54Z","timestamp":1755636534000},"page":"4137-4147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk factors for relapse of IgG4-related disease: a systematic review and meta\u2011analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Fan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6014-0635","authenticated-orcid":false,"given":"Yanying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"7641_CR1","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/1744666x.2023.2195627","volume":"19","author":"F Peyronel","year":"2023","unstructured":"Peyronel F, Fenaroli P, Maritati F, Schleinitz N, Vaglio A (2023) IgG4-related disease: advances in pathophysiology and treatment. Expert Rev Clin Immunol 19:537\u2013547. https:\/\/doi.org\/10.1080\/1744666x.2023.2195627","journal-title":"Expert Rev Clin Immunol"},{"key":"7641_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/rheumatology\/key227","volume":"58","author":"F Yunyun","year":"2019","unstructured":"Yunyun F, Yu P, Panpan Z, Xia Z, Linyi P, Jiaxin Z et al (2019) Efficacy and safety of low dose mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology (Oxford) 58:52\u201360. https:\/\/doi.org\/10.1093\/rheumatology\/key227","journal-title":"Rheumatology (Oxford)"},{"key":"7641_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/ajg.2016.40","volume":"111","author":"EL Culver","year":"2016","unstructured":"Culver EL, Sadler R, Simpson D, Cargill T, Makuch M, Bateman AC et al (2016) Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UK cohort. Am J Gastroenterol 111:733\u2013743. https:\/\/doi.org\/10.1038\/ajg.2016.40","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"7641_CR4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00535-014-0945-z","volume":"49","author":"T Kamisawa","year":"2014","unstructured":"Kamisawa T, Okazaki K, Kawa S, Ito T, Inui K, Irie H et al (2014) Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 III. treatment and prognosis of autoimmune pancreatitis. J Gastroenterol 49(6):961\u2013970. https:\/\/doi.org\/10.1007\/s00535-014-0945-z","journal-title":"J Gastroenterol"},{"key":"7641_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1067","volume":"369","author":"M Lanzillotta","year":"2020","unstructured":"Lanzillotta M, Mancuso G, Della-Torre E (2020) Advances in the diagnosis and management of IgG4 related disease. BMJ 369:m1067. https:\/\/doi.org\/10.1136\/bmj.m1067","journal-title":"BMJ"},{"key":"7641_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000004002","volume":"95","author":"P Brito-Zer\u00f3n","year":"2016","unstructured":"Brito-Zer\u00f3n P, Kostov B, Bosch X, Acar-Denizli N, Ramos-Casals M, Stone JH (2016) Therapeutic approach to IgG4-related disease: a systematic review. Medicine (Baltimore) 95:e4002. https:\/\/doi.org\/10.1097\/md.0000000000004002","journal-title":"Medicine (Baltimore)"},{"key":"7641_CR7","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/rheumatology\/kev438","volume":"55","author":"ZS Wallace","year":"2016","unstructured":"Wallace ZS, Mattoo H, Mahajan VS, Kulikova M, Lu L, Deshpande V et al (2016) Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford) 55:1000\u20131008. https:\/\/doi.org\/10.1093\/rheumatology\/kev438","journal-title":"Rheumatology (Oxford)"},{"key":"7641_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02792-z","volume":"24","author":"J Zongfei","year":"2022","unstructured":"Zongfei J, Lingli C, Ying S, Lingying M, Lijuan Z, Dongmei L et al (2022) Clinical and pathological predictors of relapse in IgG4-related disease. Arthritis Res Ther 24:106. https:\/\/doi.org\/10.1186\/s13075-022-02792-z","journal-title":"Arthritis Res Ther"},{"key":"7641_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02489-9","volume":"23","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Mou D, Wang Z, Zeng Q, Wang Z, Xue J et al (2021) Clinical features and relapse risks of IgG4-related ophthalmic disease: a single-center experience in China. Arthritis Res Ther 23:98. https:\/\/doi.org\/10.1186\/s13075-021-02489-9","journal-title":"Arthritis Res Ther"},{"key":"7641_CR10","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1002\/art.39686","volume":"68","author":"H Sekiguchi","year":"2016","unstructured":"Sekiguchi H, Horie R, Kanai M, Suzuki R, Yi ES, Ryu JH (2016) IgG4-related disease: retrospective analysis of one hundred sixty-six patients. Arthritis Rheumatol 68:2290\u20132299. https:\/\/doi.org\/10.1002\/art.39686","journal-title":"Arthritis Rheumatol"},{"key":"7641_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/rheumatology\/key397","volume":"58","author":"L Wang","year":"2019","unstructured":"Wang L, Zhang P, Zhang X, Lin W, Tang H, Li J et al (2019) Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients. Rheumatology (Oxford) 58:820\u2013830. https:\/\/doi.org\/10.1093\/rheumatology\/key397","journal-title":"Rheumatology (Oxford)"},{"key":"7641_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2215\/cjn.0000000000000193","volume":"18","author":"A Chaba","year":"2023","unstructured":"Chaba A, Devresse A, Audard V, Boffa JJ, Karras A, Cartery C et al (2023) Clinical and prognostic factors in patients with IgG4-related kidney disease. Clin J Am Soc Nephrol 18:1031\u20131040. https:\/\/doi.org\/10.2215\/cjn.0000000000000193","journal-title":"Clin J Am Soc Nephrol"},{"key":"7641_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.828122","volume":"13","author":"Y Fujita","year":"2022","unstructured":"Fujita Y, Fukui S, Umeda M, Tsuji S, Iwamoto N, Nakashima Y et al (2022) Clinical characteristics of patients with IgG4-related disease complicated by hypocomplementemia. Front Immunol 13:828122. https:\/\/doi.org\/10.3389\/fimmu.2022.828122","journal-title":"Front Immunol"},{"key":"7641_CR14","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.cgh.2017.02.007","volume":"15","author":"EL Culver","year":"2017","unstructured":"Culver EL, Sadler R, Bateman AC, Makuch M, Cargill T, Ferry B et al (2017) Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease. Clin Gastroenterol Hepatol 15:1444-1452.e1446. https:\/\/doi.org\/10.1016\/j.cgh.2017.02.007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7641_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02481-3","volume":"23","author":"L Peng","year":"2021","unstructured":"Peng L, Lu H, Zhou J, Zhang P, Li J, Liu Z et al (2021) Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study. Arthritis Res Ther 23:102. https:\/\/doi.org\/10.1186\/s13075-021-02481-3","journal-title":"Arthritis Res Ther"},{"key":"7641_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02404-8","volume":"17","author":"W An","year":"2022","unstructured":"An W, Wu Z, Li M, Yu H, Zhao X, Wang X et al (2022) Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients. Orphanet J Rare Dis 17:307. https:\/\/doi.org\/10.1186\/s13023-022-02404-8","journal-title":"Orphanet J Rare Dis"},{"key":"7641_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"7641_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10165-011-0571-z","volume":"22","author":"H Umehara","year":"2012","unstructured":"Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T et al (2012) Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22:21\u201330. https:\/\/doi.org\/10.1007\/s10165-011-0571-z","journal-title":"Mod Rheumatol"},{"key":"7641_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.41120","volume":"72","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF et al (2020) The 2019 American College of Rheumatology\/European League against rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol 72:7\u201319. https:\/\/doi.org\/10.1002\/art.41120","journal-title":"Arthritis Rheumatol"},{"key":"7641_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14397595.2020.1859710","volume":"31","author":"H Umehara","year":"2021","unstructured":"Umehara H, Okazaki K, Kawa S, Takahashi H, Goto H, Matsui S et al (2021) The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 31:529\u2013533. https:\/\/doi.org\/10.1080\/14397595.2020.1859710","journal-title":"Mod Rheumatol"},{"key":"7641_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28405-x","volume":"8","author":"M Shirakashi","year":"2018","unstructured":"Shirakashi M, Yoshifuji H, Kodama Y, Chiba T, Yamamoto M, Takahashi H et al (2018) Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Sci Rep 8:10262. https:\/\/doi.org\/10.1038\/s41598-018-28405-x","journal-title":"Sci Rep"},{"key":"7641_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"7641_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"7641_CR24","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/joim.12942","volume":"286","author":"Y Peng","year":"2019","unstructured":"Peng Y, Li JQ, Zhang PP, Zhang X, Peng LY, Chen H et al (2019) Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study. J Intern Med 286:542\u2013552. https:\/\/doi.org\/10.1111\/joim.12942","journal-title":"J Intern Med"},{"key":"7641_CR25","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1093\/rheumatology\/kez669","volume":"59","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zeng Q, Zhu L, Gao J, Wang Z, Wang Z et al (2020) Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort. Rheumatology (Oxford) 59:2115\u20132123. https:\/\/doi.org\/10.1093\/rheumatology\/kez669","journal-title":"Rheumatology (Oxford)"},{"key":"7641_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/rheumatology\/keu228","volume":"54","author":"M Yamamoto","year":"2015","unstructured":"Yamamoto M, Nojima M, Takahashi H, Yokoyama Y, Ishigami K, Yajima H et al (2015) Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment. Rheumatology (Oxford) 54:45\u201349. https:\/\/doi.org\/10.1093\/rheumatology\/keu228","journal-title":"Rheumatology (Oxford)"},{"key":"7641_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.784520","volume":"8","author":"L Gan","year":"2021","unstructured":"Gan L, Luo X, Fei Y, Peng L, Zhou J, Li J et al (2021) Long-term outcomes of IgG4-related ophthalmic disease in a Chinese IgG4-related disease cohort. Front Med 8:784520. https:\/\/doi.org\/10.3389\/fmed.2021.784520","journal-title":"Front Med"},{"issue":"7","key":"7641_CR28","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1007\/s10238-023-01123-z","volume":"23","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zeng Z, Tian H, Wang N, Wang Y, Tong J et al (2023) Clinical features and relapse risks factors of IgG4 related disease: a single-center retrospective study. Clin Exp Med 23(7):3527\u20133538. https:\/\/doi.org\/10.1007\/s10238-023-01123-z","journal-title":"Clin Exp Med"},{"key":"7641_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/joim.13814","volume":"296","author":"Y Peng","year":"2024","unstructured":"Peng Y, Wang M, Sun R, Nie Y, Zhang N, He X et al (2024) Revealing the distinct clinical patterns and relapse risk factors in seronegative IgG4-RD patients: a retrospective cohort study over a decade. J Intern Med 296:200\u2013212. https:\/\/doi.org\/10.1111\/joim.13814","journal-title":"J Intern Med"},{"key":"7641_CR30","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/1751-2980.13316","volume":"25","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wan DL, Yang ZH, Liu C, Tu YT, Liu YT et al (2024) Clinical characteristics, imaging diagnostic accuracy, and prognosis of autoimmune pancreatitis: a real-world study in China. J Dig Dis 25:615\u2013623. https:\/\/doi.org\/10.1111\/1751-2980.13316","journal-title":"J Dig Dis"},{"key":"7641_CR31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/1751-2980.12708","volume":"20","author":"M Miki","year":"2019","unstructured":"Miki M, Fujimori N, Oono T, Kawabe K, Ohno A, Matsumoto K et al (2019) Relapse patterns and predictors of IgG4-related diseases involved with autoimmune pancreatitis: a single-center retrospective study of 115 patients. J Dig Dis 20:152\u2013158. https:\/\/doi.org\/10.1111\/1751-2980.12708","journal-title":"J Dig Dis"},{"key":"7641_CR32","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00535-018-1434-6","volume":"53","author":"HW Lee","year":"2018","unstructured":"Lee HW, Moon SH, Kim MH, Cho DH, Jun JH, Nam K et al (2018) Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: long-term follow-up results after steroid therapy with short-duration maintenance treatment. J Gastroenterol 53:967\u2013977. https:\/\/doi.org\/10.1007\/s00535-018-1434-6","journal-title":"J Gastroenterol"},{"key":"7641_CR33","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s10067-020-05484-8","volume":"40","author":"J Zongfei","year":"2021","unstructured":"Zongfei J, Lingying M, Lijuan Z, Ying S, Rongyi C, Dongmei L et al (2021) Prognostic factors in IgG4-related disease: a long-term monocentric Chinese cohort study. Clin Rheumatol 40:2293\u20132300. https:\/\/doi.org\/10.1007\/s10067-020-05484-8","journal-title":"Clin Rheumatol"},{"key":"7641_CR34","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1097\/mpa.0000000000001173","volume":"47","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Ozawa M, Watanabe T, Ito T, Muraki T, Hamano H et al (2018) Predictive factors for autoimmune pancreatitis relapse after 3 years of maintenance therapy. Pancreas 47:1337\u20131343. https:\/\/doi.org\/10.1097\/mpa.0000000000001173","journal-title":"Pancreas"},{"key":"7641_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-02939-5","volume":"23","author":"Y Kiyoshita","year":"2023","unstructured":"Kiyoshita Y, Ishii Y, Serikawa M, Hanada K, Sasaki T, Fujimoto Y et al (2023) Relapse rate and predictors of relapse after cessation of glucocorticoid maintenance therapy in type 1 autoimmune pancreatitis: a multicenter retrospective study. BMC Gastroenterol 23:295. https:\/\/doi.org\/10.1186\/s12876-023-02939-5","journal-title":"BMC Gastroenterol"},{"key":"7641_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02338-1","volume":"22","author":"J Zhou","year":"2020","unstructured":"Zhou J, Peng Y, Peng L, Wu D, Li J, Jiang N et al (2020) Serum IgE in the clinical features and disease outcomes of IgG4-related disease: a large retrospective cohort study. Arthritis Res Ther 22:255. https:\/\/doi.org\/10.1186\/s13075-020-02338-1","journal-title":"Arthritis Res Ther"},{"key":"7641_CR37","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s00535-016-1302-1","volume":"52","author":"K Kubota","year":"2017","unstructured":"Kubota K, Kamisawa T, Okazaki K, Kawa S, Hirano K, Hirooka Y et al (2017) Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: a long-term Japanese multicenter analysis of 510 patients. J Gastroenterol 52:955\u2013964. https:\/\/doi.org\/10.1007\/s00535-016-1302-1","journal-title":"J Gastroenterol"},{"key":"7641_CR38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jhbp.541","volume":"25","author":"K Kubota","year":"2018","unstructured":"Kubota K, Kamisawa T, Hirano K, Hirooka Y, Uchida K, Ikeura T et al (2018) Clinical course of type 1 autoimmune pancreatitis patients without steroid treatment: a Japanese multicenter study of 97 patients. J Hepatobiliary Pancreat Sci 25:223\u2013230. https:\/\/doi.org\/10.1002\/jhbp.541","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"7641_CR39","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/j.cgh.2018.02.049","volume":"16","author":"S Majumder","year":"2018","unstructured":"Majumder S, Mohapatra S, Lennon RJ, Piovezani Ramos G, Postier N, Gleeson FC et al (2018) Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease. Clin Gastroenterol Hepatol 16:1947\u20131953. https:\/\/doi.org\/10.1016\/j.cgh.2018.02.049","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7641_CR40","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1111\/jgh.15163","volume":"35","author":"T Ishikawa","year":"2020","unstructured":"Ishikawa T, Kawashima H, Ohno E, Iida T, Suzuki H, Uetsuki K et al (2020) Risks and characteristics of pancreatic cancer and pancreatic relapse in autoimmune pancreatitis patients. J Gastroenterol Hepatol 35:2281\u20132288. https:\/\/doi.org\/10.1111\/jgh.15163","journal-title":"J Gastroenterol Hepatol"},{"key":"7641_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000315936","volume":"95","author":"C Ozdemir","year":"2010","unstructured":"Ozdemir C, Akdis M, Akdis CA (2010) T-cell response to allergens. Chem Immunol Allergy 95:22\u201344. https:\/\/doi.org\/10.1159\/000315936","journal-title":"Chem Immunol Allergy"},{"key":"7641_CR42","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/s0140-6736(14)60720-0","volume":"385","author":"T Kamisawa","year":"2015","unstructured":"Kamisawa T, Zen Y, Pillai S, Stone JH (2015) IgG4-related disease. Lancet 385:1460\u20131471. https:\/\/doi.org\/10.1016\/s0140-6736(14)60720-0","journal-title":"Lancet"},{"key":"7641_CR43","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jaci.2015.12.1330","volume":"138","author":"H Mattoo","year":"2016","unstructured":"Mattoo H, Mahajan VS, Maehara T, Deshpande V, Della-Torre E, Wallace ZS et al (2016) Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol 138:825\u2013838. https:\/\/doi.org\/10.1016\/j.jaci.2015.12.1330","journal-title":"J Allergy Clin Immunol"},{"key":"7641_CR44","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","volume":"78","author":"ZS Wallace","year":"2019","unstructured":"Wallace ZS, Zhang Y, Perugino CA, Naden R, Choi HK, Stone JH (2019) Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis 78:406\u2013412. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214603","journal-title":"Ann Rheum Dis"},{"key":"7641_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(19)30006-2","volume":"1","author":"C Terao","year":"2019","unstructured":"Terao C, Ota M, Iwasaki T, Shiokawa M, Kawaguchi S, Kuriyama K et al (2019) IgG4-related disease in the Japanese population: a genome-wide association study. Lancet Rheumatol 1:e14\u2013e22. https:\/\/doi.org\/10.1016\/s2665-9913(19)30006-2","journal-title":"Lancet Rheumatol"},{"key":"7641_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/cei.12641","volume":"181","author":"E Della-Torre","year":"2015","unstructured":"Della-Torre E, Lanzillotta M, Doglioni C (2015) Immunology of IgG4-related disease. Clin Exp Immunol 181:191\u2013206. https:\/\/doi.org\/10.1111\/cei.12641","journal-title":"Clin Exp Immunol"},{"key":"7641_CR47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/82_2016_39","volume":"401","author":"S Kawa","year":"2017","unstructured":"Kawa S (2017) The immunobiology of immunoglobulin G4 and complement activation pathways in IgG4-related disease. Curr Top Microbiol Immunol 401:61\u201373. https:\/\/doi.org\/10.1007\/82_2016_39","journal-title":"Curr Top Microbiol Immunol"},{"key":"7641_CR48","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/art.39132","volume":"67","author":"A Khosroshahi","year":"2015","unstructured":"Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN et al (2015) International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 67:1688\u20131699. https:\/\/doi.org\/10.1002\/art.39132","journal-title":"Arthritis Rheumatol"},{"key":"7641_CR49","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.semarthrit.2020.01.010","volume":"50","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhao Z, Gao D, Wang H, Liao S, Dong C et al (2020) Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: a randomized clinical trial. Semin Arthritis Rheum 50:1513\u20131520. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.01.010","journal-title":"Semin Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07641-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07641-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07641-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:25:17Z","timestamp":1760365517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07641-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7641"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07641-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Disclosures None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}